Clinical trial NCT04059757: Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD
Official title: Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute Graft Versus Host Disease
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)
Keywords: Graft Versus Host Disease (GVHD)
Lead sponsor: Case Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2019-08-16
Enrollment: 0
Sex: ALL
Minimum age (years): 19
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The study follows R. Simon's minimax two-stage phase II design with type I error of 0.05 and power of 80%. Ten participants will be enrolled on stage one. If there are 2 or less responses, the trial will be stopped and the treatment will be considered less than 60% effective for this patient population. If there are 3 or more responses, 7 additional patients will be enrolled.
Primary purpose: TREATMENT

Brief summary: Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD) is a complication of allogeneic stem cell transplant which is usually treated with steroids. You are being asked to take part in this study because you have recently been diagnosed with GI-GVHD. The standard of care for GI-aGVHD is steroids. When aGVHD does not respond to steroids it is described as steroid-refractory aGVHD. There is no standard therapy for steroid-refractory GI-aGVHD.

This study is a Phase II study. The main goal of a Phase II study is to see the efficacy and what side effects are seen with FMT as a treatment for GVHD.

Fecal Microbiota Transplantation (FMT) is the transfer of fecal material from a healthy donor to a patient in order to restore the diversity of the intestinal microbiota. FMT is currently indicated for the treatment of recurrent Clostridium Difficile infection.

FMT is considered experimental in this study, meaning it is not approved by the FDA for the treatment of GVHD.


Eligibility criteria: Inclusion Criteria:

* One of the following diagnosis:
* High risk aGVHD (either biopsy proven or clinical diagnosed) (see Appendix B \& C) as defined by either:

  * Lower gastrointestinal (GI) stage 3+
  * Hyper-acute GVHD as defined by aGVHD of the GI tract within the first 14 days of transplant AND
  * Subjects with treatment-naive acute GVHD as defined as those who have not received previous systemic treatment for acute GVHD, except for a maximum of 7 days of no less than 1 mg/kg/day of methyl-prednisolone (or equivalent dose of prednisone).

OR:

* Steroid refractory aGVHD of the GI tract (either biopsy proven or clinical diagnosed) as defined by:

  * no response to steroid treatment (minimum daily dose: 2 mg/kg methyl-prednisolone or equivalent) lasting at least 7 days, or
  * progression of at least one grade within the first 72 h of treatment
* ECOG Performance status \< 3
* Patients who underwent an allogeneic hematopoietic stem cell transplantation from any donor source.
* Patients who are able stop prophylactic antibiotics during the treatment period
* Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Active malignancy
* Patients with any concurrent uncontrolled clinically significant medical condition including active infection, laboratory abnormality, or psychiatric illness which could place the patient at unacceptable risk of study treatment.
* Pregnant or breastfeeding women
* Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
* Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
* Patients with any severe gastrointestinal condition other than GI-GVHD.
* Inability (e.g. dysphagia) to or unwilling to swallow capsules
* Active gastrointestinal infection at time of enrollment
* Known or suspected toxic megacolon and/or known small bowel ileus
* Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy
* History of total colectomy or bariatric surgery
* Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy
* Unable or unwilling to comply with protocol requirements
* Expected life expectancy \< 6 months
* Patients who have CMV \>2,000 copies/mL of whole blood or EBV \>2,000 copies/mL of whole blood.

Primary outcomes:
measure: Number of participants experiencing toxicity
timeFrame: up to 6 months from start of treatment
measure: Efficacy of FMT therapy in high risk and in steroid refractory GI-aGVHD as defined as number of responses at day 28 (+/- 3 days) post FMT treatment
timeFrame: 28 days (+/- 3 days) post FMT treatment
Secondary outcomes:
measure: Non-relapse mortality (NRM) as measured by percentage of participants who die not related to relapse
timeFrame: up to 6 months from start of treatment
measure: Relapse as measured by percentage of participants who relapse
timeFrame: up to 6 months from start of treatment
measure: Relapse-related mortality as measured by percentage of participants with death related to relapse
timeFrame: up to 6 months from start of treatment
measure: Percentage of participants who develop cGVHD by the end of trial
timeFrame: up to 6 months from start of treatment
measure: Overall survival (OS) as measured by percentage of participants who are alive at end of trial
timeFrame: up to 6 months from start of treatment
measure: Percentage of patients who discontinue steroids at the end of the study
timeFrame: up to 6 months from start of treatment
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
state: Ohio
Study officials:
affiliation: Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
name: Leland Metheny, MD
role: PRINCIPAL_INVESTIGATOR
References: